drug

IM-1617

1 story · latest Aug 11, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Immunome, Inc.

Timeline

Immunome reports Q2 2026 results, varegacestat NDA under FDA review

Aug 11Quarterly updateImmunome, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.